Inventor
Michael DORE
Inventor
CA
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%
C07DHeterocyclic compounds26%
C07BGeneral methods of organic chemistry11%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium11%
PatentTitleYear
12,544,374AZA-quinoline compounds and uses thereof202612,479,842Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease202512,473,273Quinoline compounds and compositions for inhibiting EZH2202512,209,098N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2202512,139,488Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease202412,060,353Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease202411,952,386N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP22024Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2024–2026Patents assigned to NOVARTIS AG (4)· patent assignee history
2024–2025Patents assigned to UNIV MONTREAL (3)· patent assignee history
2024–2026Based in CA· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| NOVARTIS AG | 4 | 2024–2026 |
| UNIV MONTREAL | 3 | 2024–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| CA | 7 | 2024–2026 |